Half-life Extended Drug for Disease

With more than 200 authorized recombinant protein therapeutics—which include proteins including clotting factors, hormones, growth factors, cytokines, enzymes, and antibodies—available for use in a variety of indications. Consider monoclonal antibodies as an example. Based on various half-life extension techniques, the market for these antibodies reached a valuation of about $60 billion in 2015 and is still growing at one of the fastest rates in the pharmaceutical industry.

In particular, when treating chronic conditions that need lifelong care, prolonging the plasma half-life can assist decrease patient burden and enhance quality of life by extending the period between administrations. The pharmaceutical industry has acknowledged this, and in the interim, half of the therapeutic proteins that have been approved have had their half-lives extended. Additionally, a number of cutting-edge biotherapeutics have been created to combine protein medications with useful fragments like albumin and the Fc portion.